| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
SAN CARLOS, Calif. – November 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. |
| 26 Aug 2026 |
8-K: Results of Operations and Financial Condition
On August 26, 2026, BeOne Medicines Ltd. (the “Company”) filed its 2026 Interim Report for the six months ended June 30, 2026 (the “STAR Interim Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shangha... |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
SAN CARLOS, Calif. – August 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2026. |
| 26 Jun 2026 |
8-K: Other Events
As previously disclosed in the Quarterly Report on Form 10-Q filed by BeOne Medicines Ltd. (the “Company”) with the Securities and Exchange Commission on May 6, 2026, the Company is subject to ongoing tax audits that may result in liabil... |
| 11 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The name of the plan is the BeOne Medicines Ltd. Fifth Amended and Restated 2016 Share Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consult... |
| 15 May 2026 |
8-K: Other Events
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
SAN CARLOS, Calif. – May 6, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026. |
| 14 Apr 2026 |
8-K: Results of Operations and Financial Condition
On April 14, 2026, BeOne Medicines Ltd. (the “Company”) filed its 2025 Annual Report (the “STAR Annual Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange, which was prepared in ac... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership |
| 19 Dec 2025 |
8-K: Termination of a Material Definitive Agreement
As previously disclosed in its Current Report on Form 8-K filed on November 19, 2025, BeOne Medicines Ltd. (the “Company”) entered into the Facilities Agreement (the “Facilities Agreement”), by and among (i) certain subsidiaries of the C... |
| 18 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 17, 2025, BeOne Medicines Ltd. (the “Company”) appointed Dr. Lai Wang to serve as President, Global Head of Research and Development of the Company. In this role, Dr. Wang will oversee the research and development functions a... |
| 19 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On November 13, 2025 (November 14, 2025 Hong Kong time), BeOne Medicines Ltd. (the “Company” and, together with its subsidiaries, the “Group”) entered into the Facilities Agreement (the “Facilities Agreement”), by and among (i) certain s... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
SAN CARLOS, Calif. – November 6, 2025 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. |
| 29 Aug 2025 |
8-K: Results of Operations and Financial Condition
On August 29, 2025, BeOne Medicines Ltd. (the “Company”) filed its 2025 Interim Report for the six months ended June 30, 2025 (the “STAR Interim Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shangha... |
| 25 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
SAN CARLOS, Calif. – August 25, 2025 – BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
SAN CARLOS, Calif. – August 6, 2025 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025. |
| 21 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 21, 2025, BeiGene, Ltd. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”). As disclosed in the Company’s definitive proxy statement for the Annual Meeting filed with the U.S. Securities and Exchange Co... |
| 13 May 2025 |
8-K: Unregistered Sales of Equity Securities
On May 13, 2025, in connection with the proposed re-domiciliation of BeiGene, Ltd. (the “Company”) from Cayman Islands to Switzerland (the “Continuation”), the Company entered into an internal transfer agreement with its wholly owned sub... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
SAN CARLOS, Calif. – (BUSINESS WIRE) – BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the ... |
| 29 Apr 2025 |
8-K: Other Events
On April 29, 2025, the U.S. Patent and Trademark Office (“USPTO”) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (“Pharmacyclics”) U.S. Patent No. 11,672,803 (the “Patent”) that were challenged by BeiGen... |
Loading...